Myocarditis in the Setting of Recent COVID-19 Vaccination

Table 1

Patient characteristics and results.

Patient	Age	Sex	Medical history	Symptom onset	Vaccine	Troponin T  ng/ml	Imaging	Ischemic work-up
A	25	Male	Crohn’s disease (no medications)	Chest pain 4-day post-2^nd vaccine	BNT162b2 Pfizer/BioNTech	ng/ml	EKG: no ischemic changes; Echo: left ventricular ejection %; Cardiac MRI (cMRI): %, consistent with myocardial edema (T2 mapping) and myocardial injury (focal late gadolinium enhancement (LGE)) with multiple foci in the midwall	Not applicable
B	28	Male	Obesity	Chest pain 3-day post-2^nd vaccine	BNT162b2 Pfizer/BioNTech	ng/ml	EKG: lateral ST elevation myocardial infarction; cMRI: %, consistent with myocardial edema (T2 mapping) and myocardial injury (focal LGE) in the basal inferior, mid- to distal lateral/inferolateral walls	Coronary angiogram: no luminal irregularities
C	36	Male	Gastroesophageal reflux disease	Chest pain 2-day post-2^nd vaccine	mRNA-1273 Moderna/NIH	ng/ml	EKG: lateral ST elevations; Echo: -60%; cMRI: %, consistent with myocardial edema (T2 mapping) and myocardial injury (focal LGE) in the mid- to distal inferolateral and lateral walls	Coronary angiogram: no luminal irregularities